clinical trials evaluating alternative surgical treatments or adjunctive therapy modalities for melanoma patients should incorporate these parameters into their assessment , especially in stage i ( localized ) disease where tumor thickness and the anatomical site of the primary melanoma are dominant prognostic factors .
C0012634
disease
C0027651
tumor